United States: The First Circuit Agrees that Non-Cash Reverse Payments Are Subject to Antitrust Scrutiny. Does the Loestrin Decision Point to Battles to Come?

Recently, the First Circuit became the second federal appellate court interpreting the Supreme Court's landmark decision in FTC v. Actavis, Inc.[1] to hold that non-cash "reverse payments" between pioneer and generic pharmaceutical manufacturers risk antitrust liability. Like the Third Circuit in King Drug,[2] the First Circuit's decision in In re Loestrin 24 FE Antitrust Litigation held that a pioneer drug manufacturer's agreement not to market an authorized generic product during a generic challenger's 180-day exclusivity period to settle litigation under the Hatch-Waxman Act is subject to rule of reason scrutiny under the Sherman Act.[3]  In reversing the District Court's holding that Actavis does not apply to non-cash reverse payments, Loestrin continues the trend towards expanded liability for settling parties. However, Loestrin's extensive discussion of the pleading standard applicable to Actavis' "large and unjustified payment" factor points toward future battles over the plausibility of complaints alleging non-cash reverse payments.

The dispute in Loestrin centers around Watson Pharmaceuticals, Inc.'s ("Watson") challenge to the validity of Warner Chilcott's ("Warner") patents covering the active ingredient of its drug, Loestrin 24 FE ("Loestrin"), an oral contraceptive, and Watson's plans to market its own generic version of Loestrin. To increase generic pharmaceutical competition, the Hatch-Waxman Act[4] (the "Act") provides generic manufacturers with unique incentives to challenge the patent protection accorded to pioneer drugs. Instead of requiring detailed studies demonstrating efficacy and safety, the Act permits generic challengers to "piggy-back" on the pioneer drug manufacturer's studies using an abbreviated new drug application (an "ANDA") so long as the generic challenger demonstrates bioequivalence.[5]  And, most importantly, the FDA grants the first successful ANDA filer a 180-day exclusivity period during which time other generic challengers are not permitted to market the drug.[6]  The 180-day exclusivity period can be extraordinarily valuable to the generic challenger. However, in order to market a generic drug, a generic challenger must first overcome the pioneer manufacturer's patent monopoly.

The most common form of Hatch-Waxman challenge is known as a Paragraph IV certification. Under Paragraph IV, the generic manufacturer certifies that the pioneer's patents are "invalid or will not be infringed by the manufacture, use, or sale of the [generic] drug."[7]  In almost all cases, a Paragraph IV certification provokes patent infringement litigation by the pioneer manufacturer because certification is an act of constructive infringement and the initiation of litigation triggers a 30-month stay of the FDA's consideration of the ANDA application.[8]

In Loestrin, Watson filed the first ANDA challenging Warner's patent on Loestrin and certified that its generic product did not infringe the patent and/or the patent was invalid under Paragraph IV.[9]  In January 2009, after Warner filed an infringement suit against Watson, the parties entered into a settlement agreement wherein Watson was permitted to market generic Loestrin beginning in January 2014 and Warner agreed not to market an authorized generic Loestrin product during Watson's 180-day exclusivity period.[10]  The agreement also provided fees to Watson for the co-promotion of another drug and rights to sell a third, Warner brand-name drug that was in clinical development.[11]

A group of direct purchasers and end purchasers filed complaints alleging that Warner's agreement not to market an authorized generic during Watson's exclusivity period constituted an illegal reverse payment under Section 1 of the Sherman Act.[12]  Although Actavis had already been decided at the time it reached its decision, in dismissing the purchasers' complaints, the District Court held that non-cash reverse payments, including no authorized generic agreements, are not subject to antitrust scrutiny under Actavis.[13]  The District Court explained: "Reading Actavis, this Court cannot help but find that it applies solely to monetary settlements; the narrowness of the Supreme Court's language and the cash-focused guidance for applying the rule of reason permit no other conclusion until and unless the Supreme Court expands its holding."[14]  In dismissing the complaints, the District Court further relied on Actavis' guidance that a "large and unjustified" payment to the purported generic infringer may serve as a proxy for an agreement to maintain supracompetitive prices and "requires, on the part of the plaintiff, and ultimately the reviewing court (or jury), an ability to assess or calculate the true value of the payment made by the patentee to the generic competitor."[15]  Unlike a cash settlement, the District Court held that "a non-cash settlement, particularly one that is multifaceted and complex...is almost impossible to measure against these [] factors."[16]  Accordingly, the District Court held that Actavis could not be applied to non-monetary settlements and dismissed the plaintiffs' complaints.

Rejecting the District Court's reasoning, the First Circuit held that Actavis applies to non-monetary reverse payments because "the key word used throughout the opinion is 'payment,' which connotes a much broader category of consideration than cash alone."[17]  Notwithstanding, the Loestrin Court agreed that, under Actavis, "the size of the reverse payment, particularly as it relates to potential litigation expenses, is central to the antitrust query and requires that the reviewing court or factfinder [sic] assess the value of the payment."[18]  The Circuit parted ways with the District Court, however, based on Actavis' repeated references to the size of the alleged reverse payment which, in the Circuit Court's view, presupposed that the size of the payment in question – whatever form it takes – is ascertainable.[19]  Accordingly, the First Circuit explained that "[a]lthough the value of non-cash reverse payments may be much more difficult to compute than that of their cash counterparts, antitrust litigation often requires an 'elaborate inquiry into the reasonableness of a challenged business practice' and, as a result, is 'extensive and complex.'"[20]  Stopping short of endorsing a heightening pleading standard, the court held that plaintiffs must "'estimate the value of the term, at least to the extent of determining whether it is large and unjustified.'"[21]  Because the District Court did not assess the size of the alleged reverse payment at issue, the Circuit Court remanded the case for further proceedings.

In addition to expanding reverse payment liability to non-cash reverse payments in the First Circuit, Loestrin confirms that new battle lines are being drawn in reverse payment litigation. Specifically, it appears that plaintiffs' attempts to adequately plead "large and unjustified" non-cash payments will assume greater importance and defendants' challenges to the sufficiency of such pleadings will grow in intensity. Under Iqbal and Twombly, a plaintiff must "state a claim to relief that is plausible on its face" by alleging non-conclusory "factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged."[22]  Although Loestrin holds that a plaintiff need only estimate whether the payment is large and unjustified at the pleading stage, the plausibility of such allegations are context-specific, and they must be supported by non-conclusory factual content. On remand and in the cases that follow Loestrin, litigants' ability to meet this standard will be tested.

[1] 133 S. Ct. 2223 (2013).

[2] King Drug Co. of Florence, Inc. v. SmithKline Beecham Corp., 791 F.3d 388 (3d Cir. 2015).

[3] Rochester Drug Co-Operative, Inc. v. Warner Chilcott Co. (In re Loestrin 24 FE Antirust Litig.), 2016 U.S. App. LEXIS 3049, at *28 (1st Cir. Feb. 22, 2016).

[4] 21 U.S.C. § 355, et seq.

[5] 21 U.S.C. § 355(j).

[6] 21 U.S.C. § 355(j)(5)(B)(iii), (iv).

[7] 21 U.S.C. § 355(j)(2)(A)(vii)(IV).

[8] 35 U.S.C. § 271(e)(2)(A); 21 U.S.C. § 355(j)(5)(B)(iii).

[9] Loestrin, 2016 U.S. App. LEXIS 3049, at *15.

[10] Id. at *15-16.

[11] Id. at *16-17.

[12] 15 U.S.C. § 1.

[13] In re Loestrin 24 FE Antitrust Litig., 45 F. Supp. 3d 180, 192 (D.R.I. 2014)).

[14] Id.

[15] Id. at *190.

[16] Id. at *191.

[17] Loestrin, 2016 U.S. App. LEXIS 3049, at *27.

[18] Id. at *30.

[19] Id. at *31.

[20] Id. at *32 (citation omitted).

[21] Id. at *32-33 (quoting In re Actos End Payor Antitrust Litig., 2015 U.S. Dist. LEXIS 127748, at *43, 2015 WL 5610752, at *13) (S.D.N.Y. Sep. 22, 2015). Importantly, the Loestrin Court also held that the five-factor analysis utilized by the Supreme Court in Actavis, which includes "large and unjustified" payments, does "not overhaul the rule of reason, nor should they [sic] create a new five-part framework in antitrust cases."  Loestrin, 2016 U.S. App. LEXIS 3049, at *30 n.12.

[22] Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009); Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 555-56 (2007).

The First Circuit Agrees that Non-Cash Reverse Payments Are Subject to Antitrust Scrutiny. Does the Loestrin Decision Point to Battles to Come?

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
McDermott Will & Emery
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions